Medical Devices; Availability of Safety and Effectiveness Summaries for Premarket Approval Applications, 72829-72830 [2010-29731]
Download as PDF
Federal Register / Vol. 75, No. 227 / Friday, November 26, 2010 / Notices
The estimate of the time required for
record preparation and maintenance is
based on Agency communications with
industry. Other information needed to
calculate the total burden hours (i.e.,
manufacturing sites, number of type A
medicated articles being manufactured,
etc.) are derived from Agency records
and experience.
Dated: November 19, 2010.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2010–29687 Filed 11–24–10; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Los Alamos Historical Document
Retrieval and Assessment (LAHDRA)
Project
srobinson on DSKHWCL6B1PROD with NOTICES
The Centers for Disease Control and
Prevention (CDC) and the Agency for
Toxic Substances and Disease Registry
(ATSDR) announces the following
meeting.
Name: Public Meeting to release CDC’s
recommendations to the Department of
Energy resulting from the release of the Final
Report of the Los Alamos Historical
Document Retrieval and Assessment
(LAHDRA)Project.
Time and Date: 5 p.m.–7 p.m., (Mountain
Time), Wednesday, December 8, 2010 and 5
p.m.–7 p.m. Thursday, December 9, 2010.
Place: December 8, 2010, Santa Claran
Hotel & Casino in Espanola (25 miles north
of Santa Fe on US 84/285), 460 Riverside
Drive, Espanola, New Mexico 87532,
telephone 877–505–4949.
December 9, 2010, Tularosa Senior &
Community Center in Tularosa (14 miles
north of Alamogordo on US 70), 1050
Bookout Rd., Tularosa, New Mexico 88352,
telephone 575–585–4532.
Status: Open to the public, limited only by
the space available. The meeting room(s)
accommodates approximately 100 people.
Background: Under a Memorandum of
Understanding (MOU) signed in December
1990 with the Department of Energy (DOE)
and replaced by MOUs signed in 1996 and
2000, the Department of Health and Human
Services (HHS) was given the responsibility
and resources for conducting analytic
epidemiologic investigations of residents of
communities in the vicinity of DOE facilities,
workers at DOE facilities, and other persons
potentially exposed to radiation or to
potential hazards from non-nuclear energy
production use. HHS delegated program
responsibility to CDC.
In addition, a memo was signed in October
1990 and renewed in November 1992, 1996,
and in 2000, between the Agency for Toxic
Substances and Disease Registry (ATSDR)
and DOE. The MOU delineates the
responsibilities and procedures for ATSDR’s
VerDate Mar<15>2010
16:32 Nov 24, 2010
Jkt 223001
public health activities at DOE sites required
under sections 104, 105, 107, and 120 of the
Comprehensive Environmental Response,
Compensation, and Liability Act (CERCLA or
a Superfund). These activities include health
consultations and public health assessments
at DOE sites listed on, or proposed for, the
Superfund National Priorities List and at
sites that are the subject of petitions from the
public; and other health-related activities
such as epidemiologic studies, health
surveillance, exposure and disease registries,
health education, substance-specific applied
research, emergency response, and
preparation of toxicological profiles.
Purpose: This study group was charged
with locating, evaluating, cataloguing, and
copying documents that contain information
about historical chemical or radionuclide
releases from facilities at the Los Alamos
National Laboratory and Trinity Site since its
inception. The purpose of this meeting is to
release the CDC’s recommendations to the
Department of Energy as a result of the
release of the Final Report (https://
www.Lahdra.org).
Matters to Be Discussed: Agenda items for
the December 8th meeting include a
presentation from the National Center for
Environmental Health (NCEH) and poster
sessions on various report topics. There will
be time for the public to ask questions. At the
December 9th meeting, ChemRisk personnel
will present on the Final Report’s Trinity Site
chapter. All agenda items are subject to
change as priorities dictate.
Contact Person for Additional Information:
Phillip R. Green, Public Health Advisor,
Radiation Studies Branch, Division of
Environmental Hazards and Health Effects,
NCEH, CDC, 1600 Clifton Road, NE.,
(Mailstop F–58), Atlanta, Georgia 30333,
telephone 770/488–3748, fax 770/488–1539,
or e-mail address: prg1@cdc.gov.
Dated: November 19, 2010.
Tanja Popovic,
Deputy Associate Director for Science,
Centers for Disease Control and Prevention.
[FR Doc. 2010–29778 Filed 11–24–10; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket Nos. FDA–2010–M–0402, FDA–
2010–M–0361, and FDA–2010–M–0519]
Medical Devices; Availability of Safety
and Effectiveness Summaries for
Premarket Approval Applications
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is publishing a
list of premarket approval applications
(PMAs) that have been approved. This
list is intended to inform the public of
the availability of safety and
SUMMARY:
PO 00000
Frm 00050
Fmt 4703
Sfmt 4703
72829
effectiveness summaries of approved
PMAs through the Internet and the
Agency’s Division of Dockets
Management.
ADDRESSES: Submit written requests for
copies of summaries of safety and
effectiveness data to the Division of
Dockets Management (HFA–305), Food
and Drug Administration, 5630 Fishers
Lane, rm. 1061, Rockville, MD 20852.
Please cite the appropriate docket
number as listed in table 1 of this
document when submitting a written
request. See the SUPPLEMENTARY
INFORMATION section for electronic
access to the summaries of safety and
effectiveness.
FOR FURTHER INFORMATION CONTACT:
Nicole Wolanski, Center for Devices and
Radiological Health, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 66, rm. 1650, Silver Spring,
MD 20993–0002, 301–796–6570.
SUPPLEMENTARY INFORMATION:
I. Background
In the Federal Register of January 30,
1998 (63 FR 4571), FDA published a
final rule that revised 21 CFR 814.44(d)
and 814.45(d) to discontinue individual
publication of PMA approvals and
denials in the Federal Register. Instead,
the Agency now posts this information
on the Internet on FDA’s home page at
https://www.fda.gov. FDA believes that
this procedure expedites public
notification of these actions because
announcements can be placed on the
Internet more quickly than they can be
published in the Federal Register, and
FDA believes that the Internet is
accessible to more people than the
Federal Register.
In accordance with section 515(d)(4)
and (e)(2) of the Federal Food, Drug, and
Cosmetic Act (the FD&C Act) (21 U.S.C.
360e(d)(4) and (e)(2)), notification of an
order approving, denying, or
withdrawing approval of a PMA will
continue to include a notice of
opportunity to request review of the
order under section 515(g) of the FD&C
Act. The 30-day period for requesting
reconsideration of an FDA action under
§ 10.33(b) (21 CFR 10.33(b)) for notices
announcing approval of a PMA begins
on the day the notice is placed on the
Internet. Section 10.33(b) provides that
FDA may, for good cause, extend this
30-day period. Reconsideration of a
denial or withdrawal of approval of a
PMA may be sought only by the
applicant; in these cases, the 30-day
period will begin when the applicant is
notified by FDA in writing of its
decision.
The regulations provide that FDA
publish a quarterly list of available
E:\FR\FM\26NON1.SGM
26NON1
72830
Federal Register / Vol. 75, No. 227 / Friday, November 26, 2010 / Notices
safety and effectiveness summaries of
PMA approvals and denials that were
announced during that quarter. The
following is a list of approved PMAs for
which summaries of safety and
effectiveness were placed on the
Internet from July 1, 2010, through
September 30, 2010. There were no
denial actions during this period. The
list provides the manufacturer’s name,
the product’s generic name or the trade
name, and the approval date.
TABLE 1—LIST OF SAFETY AND EFFECTIVENESS SUMMARIES FOR APPROVED PMAS MADE AVAILABLE FROM JULY 1,
2010, THROUGH SEPTEMBER 30, 2010
PMA No.
Docket No.
Applicant
Trade name
P080027, FDA–2010–M–0402 ...............
OraSure Technologies, Inc ...................
P050034, FDA–2010–M–0361 ...............
Vision Care Ophthalmic Technologies,
Ltd.
Abbott Molecular, Inc ............................
ORAQUICK HCV RAPID ANTIBODY
TEST.
IMPLANTABLE MINIATURE TELESCOPE.
ABBOTT REALTIME HBV ASSAY .......
P080026, FDA–2010–M–0519 ...............
II. Electronic Access
Persons with access to the Internet
may obtain the documents at https://
www.fda.gov/cdrh/pmapage.html.
Interested organizations should monitor
the Federal Business Opportunities Web
site for all information relating to the
RFP.
Dated: November 18, 2010.
Nancy K. Stade,
Deputy Director for Policy, Center for Devices
and Radiological Health.
ADDRESSES:
[FR Doc. 2010–29731 Filed 11–24–10; 8:45 am]
BILLING CODE 4160–01–P
Proposals for the contracts
must be submitted to the Centers for
Medicare & Medicaid Services,
Acquisitions and Grants Groups,
OAGM, Attn.: Naomi Haney-Ceresa,
7500 Security Boulevard, Mail Stop C2–
21–15, Baltimore, Maryland 21244–
1850.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
FOR FURTHER INFORMATION CONTACT:
Centers for Medicare & Medicaid
Services
SUPPLEMENTARY INFORMATION:
Alfreda Staton, (410) 786–4194.
I. Background
[CMS–3229–N]
Medicare Program; Quality
Improvement Organization (QIO)
Contracts: Solicitation of Proposals
From In-State QIOs—Idaho, Maine,
South Carolina, and Vermont
Centers for Medicare &
Medicaid Services (CMS), HHS.
ACTION: Notice.
AGENCY:
This notice fulfills the
Secretary’s obligation under section
1153(i) of the Social Security Act (the
Act) to provide at least 6 months’
advance notice of the expiration dates of
contracts with out-of-State Quality
Improvement Organizations (QIOs)
before renewing any of those QIOs’
contracts. It also specifies the period of
time in which in-State QIOs may submit
a proposal for those contracts.
DATES: Interested organizations may
submit a proposal to perform the QIO
work in any of the States listed in this
announcement. The request for proposal
(RFP) will be made available to all
interested organizations through the
Federal Business Opportunities (https://
www.fedbizopps.gov) Web site. CMS
anticipates that the RFP for the QIO
contracts will be released sometime
during the month of February 2011.
srobinson on DSKHWCL6B1PROD with NOTICES
SUMMARY:
VerDate Mar<15>2010
16:32 Nov 24, 2010
Jkt 223001
The Peer Review Improvement Act of
1982 (title I, subtitle C of the Tax Equity
and Fiscal Responsibility Act of 1982
(TEFRA), Pub. L. 97–248) amended Part
B of title XI of the Act (the Act) by
establishing the Utilization and Quality
Control Peer Review Organization
program.
Utilization and Quality Control Peer
Review Organizations, now known as
Quality Improvement Organizations
(QIOs), currently review certain health
care services furnished under title XVIII
of the Social Security Act (the Act)
(Medicare) to determine whether those
services are reasonable, medically
necessary, provided in the appropriate
setting, and are of a quality that meets
professionally recognized standards.
QIO activities are a part of the Health
Care Quality Improvement Program
(HCQIP), a program that supports our
mission to ensure health care quality for
our beneficiaries. The HCQIP rests on
the belief that a plan’s, provider’s, or
practitioner’s own internal quality
management system is key to good
performance. The HCQIP is carried out
locally by the QIO in each State. Under
the HCQIP, QIOs provide critical tools
(for example, quality indicators and
information) for plans, providers, and
practitioners to improve the quality of
PO 00000
Frm 00051
Fmt 4703
Sfmt 4703
Approval date
June 25, 2010.
July 1, 2010.
August 13, 2010.
care provided to Medicare beneficiaries.
The Congress created the QIO program
in part to redirect, simplify, and
enhance the cost-effectiveness and
efficiency of the peer review process.
In June 1984, we began awarding
contracts to QIOs. We currently
maintain 53 QIO contracts with
organizations that provide medical
review activities for the 50 States, the
District of Columbia, Puerto Rico, and
the Virgin Islands. The organizations
that are eligible to contract as QIOs have
satisfactorily demonstrated that they are
either physician-sponsored or
physician-access organizations in
accordance with section 1152 of the Act
and our regulations at 42 CFR 475.102
and 475.103. A physician-sponsored
organization is one that is both
composed of a substantial number of the
licensed doctors of medicine and
osteopathy practicing medicine or
surgery in the respective review area
and who are representative of the
physicians practicing in the review area.
A physician-access organization is one
that has available to it, by arrangement
or otherwise, the services of a sufficient
number of licensed doctors of medicine
or osteopathy practicing medicine or
surgery in the review area to ensure
adequate peer review of the services
furnished by the various medical
specialties and subspecialties. In
addition, a QIO cannot be a health care
facility, health care facility association,
a health care facility affiliate, or in most
cases a payor organization. (The
regulations provide that, in the event
CMS determines no otherwise qualified
non-payor organization is available to
undertake a given QIO contract, CMS
may select a payor organization which
otherwise meets certain requirements to
be eligible to conduct Utilization and
Quality Control Peer Review as
specified in Part B of Title XI of the Act
and its implementing regulations.)
Section 1152(2) of the Act requires QIOs
to perform review functions in an
E:\FR\FM\26NON1.SGM
26NON1
Agencies
[Federal Register Volume 75, Number 227 (Friday, November 26, 2010)]
[Notices]
[Pages 72829-72830]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-29731]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket Nos. FDA-2010-M-0402, FDA-2010-M-0361, and FDA-2010-M-0519]
Medical Devices; Availability of Safety and Effectiveness
Summaries for Premarket Approval Applications
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is publishing a list of
premarket approval applications (PMAs) that have been approved. This
list is intended to inform the public of the availability of safety and
effectiveness summaries of approved PMAs through the Internet and the
Agency's Division of Dockets Management.
ADDRESSES: Submit written requests for copies of summaries of safety
and effectiveness data to the Division of Dockets Management (HFA-305),
Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville,
MD 20852. Please cite the appropriate docket number as listed in table
1 of this document when submitting a written request. See the
SUPPLEMENTARY INFORMATION section for electronic access to the
summaries of safety and effectiveness.
FOR FURTHER INFORMATION CONTACT: Nicole Wolanski, Center for Devices
and Radiological Health, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 66, rm. 1650, Silver Spring, MD 20993-0002, 301-
796-6570.
SUPPLEMENTARY INFORMATION:
I. Background
In the Federal Register of January 30, 1998 (63 FR 4571), FDA
published a final rule that revised 21 CFR 814.44(d) and 814.45(d) to
discontinue individual publication of PMA approvals and denials in the
Federal Register. Instead, the Agency now posts this information on the
Internet on FDA's home page at https://www.fda.gov. FDA believes that
this procedure expedites public notification of these actions because
announcements can be placed on the Internet more quickly than they can
be published in the Federal Register, and FDA believes that the
Internet is accessible to more people than the Federal Register.
In accordance with section 515(d)(4) and (e)(2) of the Federal
Food, Drug, and Cosmetic Act (the FD&C Act) (21 U.S.C. 360e(d)(4) and
(e)(2)), notification of an order approving, denying, or withdrawing
approval of a PMA will continue to include a notice of opportunity to
request review of the order under section 515(g) of the FD&C Act. The
30-day period for requesting reconsideration of an FDA action under
Sec. 10.33(b) (21 CFR 10.33(b)) for notices announcing approval of a
PMA begins on the day the notice is placed on the Internet. Section
10.33(b) provides that FDA may, for good cause, extend this 30-day
period. Reconsideration of a denial or withdrawal of approval of a PMA
may be sought only by the applicant; in these cases, the 30-day period
will begin when the applicant is notified by FDA in writing of its
decision.
The regulations provide that FDA publish a quarterly list of
available
[[Page 72830]]
safety and effectiveness summaries of PMA approvals and denials that
were announced during that quarter. The following is a list of approved
PMAs for which summaries of safety and effectiveness were placed on the
Internet from July 1, 2010, through September 30, 2010. There were no
denial actions during this period. The list provides the manufacturer's
name, the product's generic name or the trade name, and the approval
date.
Table 1--List of Safety and Effectiveness Summaries for Approved PMAs Made Available From July 1, 2010, Through
September 30, 2010
----------------------------------------------------------------------------------------------------------------
PMA No. Docket No. Applicant Trade name Approval date
----------------------------------------------------------------------------------------------------------------
P080027, FDA-2010-M-0402......... OraSure Technologies, ORAQUICK HCV RAPID June 25, 2010.
Inc. ANTIBODY TEST.
P050034, FDA-2010-M-0361......... Vision Care Ophthalmic IMPLANTABLE MINIATURE July 1, 2010.
Technologies, Ltd. TELESCOPE.
P080026, FDA-2010-M-0519......... Abbott Molecular, Inc... ABBOTT REALTIME HBV August 13, 2010.
ASSAY.
----------------------------------------------------------------------------------------------------------------
II. Electronic Access
Persons with access to the Internet may obtain the documents at
https://www.fda.gov/cdrh/pmapage.html.
Dated: November 18, 2010.
Nancy K. Stade,
Deputy Director for Policy, Center for Devices and Radiological Health.
[FR Doc. 2010-29731 Filed 11-24-10; 8:45 am]
BILLING CODE 4160-01-P